Revumenib is now the sole targeted therapy recommended by the National Comprehensive Cancer Network for KMT2A-rearranged acute leukemia, which opens a path for payers, said Ivo Abraham, PhD, RN, of ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

A new study offers insights into the relative efficacy of various treatments for alopecia areata (AA), suggesting that ...

New biomarkers enhance multiple sclerosis (MS) diagnosis, enabling earlier detection and improved patient care, transforming ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

ATLAS trial investigator Guy Young, MD, Children's Hospital Los Angeles and University of Southern California Keck School of ...

Panelists discuss the drivers and consequences of delayed diagnosis in hidradenitis suppurativa, emphasizing the need for ...

The symptoms of dry eye are multifactorial, says Mina Massaro-Giordano, MD, making identifying and treating dry eye important ...

National Minority Mental Health Month emphasizes the persistent mental health disparities among US racial and ethnic ...

The JAKoMo study highlights ruxolitinib's long-term efficacy and safety in myelofibrosis, showing improved quality of life ...

These interviews are the top episodes, by listens, from among the 21 podcast episodes The American Journal of Managed Care® ...